본문 바로가기
KERD
논문KCI 등재

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies

문병인|Tae Hyun Kim|Anbok Lee
대한진단검사의학회 (Korean Society For Laboratory Medicine)|2020.03|Annals of Laboratory Medicine|제40권 제2호|pp. 114-121|DOI 10.3343/alm.2020.40.2.114

1

조회

0

다운로드

2

인용

0

참고문헌

키워드

PreventionTreatmentBreast cancerOvarian cancerBRCA1/BRCA2 pathogenic variant
주제분류병리학

초록

Hereditary breast cancer is known for its strong tendency of inheritance. Most hereditary breast cancers are related to BRCA1/BRCA2 pathogenic variants. The lifelong risk of breast cancer in pathogenic BRCA1 and BRCA2 variant carriers is approximately 65% and 45%, respectively, whereas that of ovarian cancer is estimated to be 39% and 11%, respectively. Therefore, understanding these variants and clinical knowledge on their occurrence in breast cancers and carriers are important. BRCA1 pathogenic variant breast cancer shows more aggressive clinicopathological features than the BRCA2 pathogenic variant breast cancer. Compared with sporadic breast cancer, their prognosis is still debated. Treatments of BRCA1/BRCA2 pathogenic variant breast cancer are similar to those for BRCA-negative breast cancer, mainly including surgery, radiotherapy, and chemotherapy. Recently, various clinical trials have investigated poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor treatment for advanced-stage BRCA1/BRCA2 pathogenic variant breast cancer. Among the various PARP inhibitors, olaparib and talazoparib, which reached phase III clinical trials, showed improvement of median progression-free survival around three months. Preventive and surveillance strategies for BRCA pathogenic variant breast cancer to reduce cancer recurrence and improve treatment outcomes have recently received increasing attention. In this review, we provide an information on the clinical features of BRCA1/BRCA2 pathogenic variant breast cancer and clinical recommendations for BRCA pathogenic variant carriers, with a focus on treatment and prevention strategies. With this knowledge, clinicians could manage the BRCA1/BRCA2 pathogenic variant breast cancer patients more effectively.

Abstract

Hereditary breast cancer is known for its strong tendency of inheritance. Most hereditary breast cancers are related to BRCA1/BRCA2 pathogenic variants. The lifelong risk of breast cancer in pathogenic BRCA1 and BRCA2 variant carriers is approximately 65% and 45%, respectively, whereas that of ovarian cancer is estimated to be 39% and 11%, respectively. Therefore, understanding these variants and clinical knowledge on their occurrence in breast cancers and carriers are important. BRCA1 pathogenic variant breast cancer shows more aggressive clinicopathological features than the BRCA2 pathogenic variant breast cancer. Compared with sporadic breast cancer, their prognosis is still debated. Treatments of BRCA1/BRCA2 pathogenic variant breast cancer are similar to those for BRCA-negative breast cancer, mainly including surgery, radiotherapy, and chemotherapy. Recently, various clinical trials have investigated poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor treatment for advanced-stage BRCA1/BRCA2 pathogenic variant breast cancer. Among the various PARP inhibitors, olaparib and talazoparib, which reached phase III clinical trials, showed improvement of median progression-free survival around three months. Preventive and surveillance strategies for BRCA pathogenic variant breast cancer to reduce cancer recurrence and improve treatment outcomes have recently received increasing attention. In this review, we provide an information on the clinical features of BRCA1/BRCA2 pathogenic variant breast cancer and clinical recommendations for BRCA pathogenic variant carriers, with a focus on treatment and prevention strategies. With this knowledge, clinicians could manage the BRCA1/BRCA2 pathogenic variant breast cancer patients more effectively.

참고문헌 (97)

  1. Mahdavi M, "Hereditary breast cancer; genetic penetrance and current status with BRCA", J Cell Physiol, 234, pp.5741~5750 (2019)
  2. Ford D, "Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium", Am J Hum Genet, 62, pp.676~689 (1998)
  3. Antoniou A, "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies", Am J Hum Genet, 72, pp.1117~1130 (2003)
  4. Thompson D, "Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers", J Natl Cancer Inst, 94, pp.1358~1365 (2002)
  5. Veronesi A, "Familial breast cancer : characteristics and outcome of BRCA 1-2 positive and negative cases", BMC Cancer, 5, pp.70~ (2005)
  6. Debniak T, "Common variants of DNA repair genes and malignant melanoma", Eur J Cancer, 44, pp.110~114 (2008)
  7. Kadouri L, "Cancer risks in carriers of the BRCA1", 2 Ashkenazi founder mutations, 2007, pp.44, 467~471
  8. Cybulski C, "BRCA1 mutations and prostate cancer in Poland", Eur J Cancer Prev, 17, pp.62~66 (2008)
  9. Suchy J, "BRCA1 mutations and colorectal cancer in Poland", Fam Cancer, 9, pp.541~544 (2010)
  10. Moynahan ME, "BRCA1 controls homology-directed DNA repair", Mol Cell, 4, pp.511~518 (1999)
  11. Moynahan ME, "BRCA2 is required for homology-directed repair of chromosomal breaks", Mol Cell, 7, pp.263~272 (2001)
  12. Scully R, "Association of BRCA1 with Rad51 in mitotic and meiotic cells", Cell, 88, pp.265~275 (1997)
  13. Orban TI, "Emerging roles of BRCA1 alternative splicing", Mol Pathol, 56, pp.191~197 (2003)
  14. Stecklein SR, "Genetic and epigenetic signatures of breast cancer subtypes", Front Biosci(Elite Ed), 4, pp.934~949 (2012)
  15. D’Andrea AD, "The Fanconi anaemia", BRCA pathway, 2003, pp.3, 23~34
  16. Albertsen H, "Genetic mapping of the BRCA1 region on chromosome 17q21", Am J Hum Genet, 54, pp.516~525 (1994)
  17. Wooster R, "Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13", Science, 265, pp.2088~2090 (1994)
  18. Bork P, "Internal repeats in the BRCA2 protein sequence", Nat Genet, 13, pp.22~23 (1996)
  19. Chen PL, "The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment", Proc Natl Acad Sci U S A, 95, pp.5287~5292 (1998)
  20. Wong AK, "RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2", J Biol Chem, 272, pp.31941~31944 (1997)
  21. Chen J, "Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells", Mol Cell, 2, pp.317~328 (1998)
  22. Petrucelli N, "Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2", Genet Med, 12, pp.245~259 (2010)
  23. Ford D, "Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium", Lancet, 343, pp.692~695 (1994)
  24. Breast Cancer Linkage Consortium, "Cancer risks in BRCA2 mutation carriers", J Natl Cancer Inst, 91, pp.1310~1316 (1999)
  25. 김성원, "한국인 유전성 유방암", 대한의사협회지, 52(10), pp.952~962 (2009), 대한의사협회
  26. Dai X, "Breast cancer cell line classification and its relevance with breast tumor subtyping", J Cancer, 8, pp.3131~3141 (2017)
  27. Carey LA, "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study", JAMA, 295, pp.2492~2502 (2006)
  28. Dent R, "Triple negative breast cancer : clinical features and patterns of recurrence", Clin Cancer Res, 13, pp.4429~4434 (2007)
  29. Brewster AM, "Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry", Lancet Oncol, 15, pp.e625~e634 (2014)
  30. Peshkin BN, "BRCA1", 2 mutations and triple negative breast cancers, 2010, pp.32, 25~33
  31. Ansquer Y, "Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group", Lancet, 352, pp.541~ (1998)
  32. Chappuis PO, "Germline BRCA1", 2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer, 2000, pp.18, 4045~4052
  33. Stoppa-Lyonnet D, "Familial invasive breast cancers : worse outcome related to BRCA1 mutations", J Clin Oncol, 18, pp.4053~4059 (2000)
  34. El-Tamer M, "Survival and recurrence after breast cancer in BRCA1", 2 mutation carriers, 2004, pp.11, 157~164
  35. van den Broek AJ, "Worse breast cancer prognosis of BRCA1", BRCA2 mutation carriers : what’s the evidence? A systematic review with meta-analysis, 2015, pp.10, e0120189~
  36. Copson ER, "Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study", Lancet Oncol, 19, pp.169~180 (2018)
  37. Baretta Z, "Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis", Med (Baltimore), 95, pp.e4975~ (2016)
  38. Pierce LJ, "Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy", Breast Cancer Res Treat, 121, pp.389~398 (2010)
  39. Vallard A, "Is breast-conserving therapy adequate in BRCA 1", 2 mutation carriers? The radiation oncologist’s point of view, 2019, pp.92, 20170657~
  40. Kirova YM, "Is the breast-conserving treatment with radiotherapy appropriate in BRCA1", 2 mutation carriers? Long-term results and review of the literature, 2010, pp.120, 119~126
  41. Pierce LJ, "Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1", 2 mutations, 2000, pp.18, 3360~3369
  42. Valachis A, "Surgical management of breast cancer in BRCA-mutation carriers : a systematic review and meta-analysis", Breast Cancer Res Treat, 144, pp.443~455 (2014)
  43. Iglehart JD, "Synthetic lethality--a new direction in cancer-drug development", N Engl J Med, 361, pp.189~191 (2009)
  44. Carey LA, "PARP and cancer--if it’s broke, don’t fix it", N Engl J Med, 364, pp.277~279 (2011)
  45. Kennedy RD, "The role of BRCA1 in the cellular response to chemotherapy", J Natl Cancer Inst, 96, pp.1659~1668 (2004)
  46. Bhattacharyya A, "The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin", J Biol Chem, 275, pp.23899~23903 (2000)
  47. Fedier A, "The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells", Int J Oncol, 22, pp.1169~1173 (2003)
  48. Tassone P, "BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells", Br J Cancer, 88, pp.1285~1291 (2003)
  49. Chabalier C, "BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance", Cell Cycle, 5, pp.1001~1007 (2006)
  50. Arun B, "Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience", J Clin Oncol, 29, pp.3739~3746 (2011)
  51. Kriege M, "The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers", Cancer, 118, pp.899~907 (2012)
  52. Zimmer AS, "Update on PARP inhibitors in breast cancer", Curr Treat Options Oncol, 19, pp.21~ (2018)
  53. Helleday T, "The underlying mechanism for the PARP and BRCA synthetic lethality : clearing up the misunderstandings", Mol Oncol, 5, pp.387~393 (2011)
  54. Javle M, "The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy", Ther Adv Med Oncol, 3, pp.257~267 (2011)
  55. Lord CJ, "PARP inhibitors : synthetic lethality in the clinic", Science, 355, pp.1152~1158 (2017)
  56. Robson M, "Olaparib for metastatic breast cancer in patients with a germline BRCA mutation", N Engl J Med, 377, pp.523~533 (2017)
  57. Litton JK, "Talazoparib in patients with advanced breast cancer and a germline BRCA mutation", N Engl J Med, 379, pp.753~763 (2018)
  58. Thomas HD, "Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial", Mol Cancer Ther, 6, pp.945~956 (2007)
  59. Drew Y, "Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer", Br J Cancer, 114, pp.723~730 (2016)
  60. Sandhu SK, "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial", Lancet Oncol, 14, pp.882~892 (2013)
  61. Lee JM, "Phase I", Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses, 2014, 106~
  62. Balmaña J, "Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors", Ann Oncol, 25, pp.1656~1663 (2014)
  63. Miller K, "Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of Hoosier Oncology Group BRE09-146", J Clin Oncol, 33(S15), pp.1082~ (2015)
  64. Wilson RH, "A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours", Br J Cancer, 116, pp.884~892 (2017)
  65. ) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2-(BRCA)-associated metastatic breast cancer (MBC), "J Clin Oncol", 2015, 520~
  66. Han HS, "Veliparib with temozolomide or carboplatin", paclitaxel versus placebo with carboplatin, 2 locally recurrent, pp.metastatic breast cancer: randomized phase II study, Ann Oncol[DOI]
  67. Tung N, "Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features", Breast Cancer Res, 12, pp.R12~ (2010)
  68. Mavaddat N, "Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1", 2 (CIMBA), 2012, pp.21, 134~147
  69. Larsen MJ, "Classifications within molecular subtypes enables identification of BRCA1", BRCA2 mutation carriers by RNA tumor profiling, 2013, pp.8, e64268~
  70. Shah PD, "Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status", Cancer, 122, pp.1178~1184 (2016)
  71. Tutt A, "Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial", Lancet, 376, pp.235~244 (2010)
  72. Kaufman B, "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1", 2 mutation, 2015, pp.33, 244~250
  73. Turner NC, "A Phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1", 2 mutations (ABRAZO), 2019, pp.25, 2717~2724
  74. Biglia N, "Breast cancer treatment in mutation carriers : surgical treatment", Minerva Ginecol, 68, pp.548~556 (2016)
  75. Li X, "Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review", Clin Cancer Res, 22, pp.3971~3981 (2016)
  76. Domchek SM, "Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality", JAMA, 304, pp.967~975 (2010)
  77. Satagopan JM, "Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations", Clin Cancer Res, 8, pp.3776~3781 (2002)
  78. King MC, "Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2", Science, 302, pp.643~646 (2003)
  79. Rebbeck TR, "Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers", J Natl Cancer Inst, 101, pp.80~87 (2009)
  80. Kauff ND, "Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study", J Clin Oncol, 26, pp.1331~1337 (2008)
  81. King MC, "Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial", JAMA, 286, pp.2251~2256 (2001)
  82. Phillips KA, "Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers", J Clin Oncol, 31, pp.3091~3099 (2013)
  83. Behan LA, "Aromatase inhibitors for prevention of breast cancer in postmenopausal women : a narrative review", Menopause, 22, pp.342~350 (2015)
  84. Runowicz CD, "American Cancer Society", American Society of Clinical Oncology breast cancer survivorship care guideline, 2016, pp.66, 43~73
  85. NCCN, "The NCCN Clinical Practice Guidelines in Oncology, genetic", familial high-risk assessment: breast and ovarian. 3.2019 version, 2019
  86. US Preventive Services Task Force, "Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer US Preventive Services Task Force Recommendation Statement", JAMA, 322, pp.652~665 (2019)
  87. Struewing JP, "The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews", N Engl J Med, 336, pp.1401~1408 (1997)
  88. Burke W, "Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium", JAMA, 277, pp.997~1003 (1997)
  89. Scheuer L, "Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers", J Clin Oncol, 20, pp.1260~1268 (2002)
  90. Saslow D, "American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography", CA Cancer J Clin, 57, pp.75~89 (2007)
  91. Woodward ER, "Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective", BJOG, 114, pp.1500~1509 (2007)
  92. Baumiller RC, "Code of ethical principles for genetics professionals : an explication", Am J Med Genet, 65, pp.179~183 (1996)
  93. Liede A, "Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2 : a review of the literature", J Clin Oncol, 22, pp.735~742 (2004)
  94. Kirchhoff T, "Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer", J Natl Cancer Inst, 96, pp.68~70 (2004)
  95. Niell BL, "BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer", J Natl Cancer Inst, 96, pp.15~21 (2004)
  96. Garber JE, "One less thing to worry about : the shrinking spectrum of tumors in BRCA founder mutation carriers", J Natl Cancer Inst, 96, pp.2~3 (2004)
  97. Korean Hereditary Breast Cancer Study group, "Hereditary Breast Cancer", pp.393~394 (2012), KOONJA publishing

관련 논문AI추천

Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients김성원, 김은규, 박소연대한병리학회 · Journal of Pathology and Translational Medicine2020 · 제54권 제4호Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients권원경, 김석원, 김종원, 남석진, 방윤주, 유재민, 유종한, 이세경, 이정언, 채병주대한암학회 · Cancer Research and Treatment2022 · 제54권 제3호Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers강한성, 강혁조, 공선영, 박보람, 박보영, 박상윤, 박수진, 이시연, 이은경, 이은숙, 임명철, 정소연, 주정남, 한재홍대한암학회 · Cancer Research and Treatment2019 · 제51권 제1호Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant김성원, 김은규, 민준원, 박우찬, 박지수, 박형석, 유재민, 유지영, 이정언, 이지연, 임석아, 정소연대한암학회 · Cancer Research and Treatment2020 · 제52권 제3호Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review권병수, 김기형, 변정미, 서동수, 신경화, 이태화, 이현주, 정대훈대한암학회 · Cancer Research and Treatment2019 · 제51권 제3호From Genetic Testing to Treatment and Prevention of BRCA-Related Breast CancerChang-Seok Ki대한진단검사의학회 · Annals of Laboratory Medicine2020 · 제40권 제2호

이 간행물의 다른 논문 (17건)

Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision MedicineSoo-Youn Leepp. 95-96Hepcidin and Neutrophil Gelatinase-Associated Lipocalin as a Biomarker for Acute Kidney Injury Linked Iron Metabolism조선영, Mina Hurpp. 97-98From Genetic Testing to Treatment and Prevention of BRCA-Related Breast CancerChang-Seok Kipp. 99-100Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of ImmunogenicityMariangela Manfredi, Roberto Verna, Maurizio Benucci, Valentina Grossi, Arianna Damiani, Maria Infantino, Paolo Moscato, Luigi Cinquanta, Elisa Gremese, Barbara Tolusso, Luca Petricca, Anna Laura Fedele, Stefano Alivernini, Fabiola Atzeni, Giovanni Minisolapp. 101-113Performance Evaluation of Body Fluid Cellular Analysis Using the Beckman Coulter UniCel DxH 800, Sysmex XN-350, and UF-5000 Automated Cellular AnalyzersJoowon Oh, Jooyoung Cho, Sang-Guk Lee, You-Hee Lee, Jaewoo Song, Jeong-HoKimpp. 122-130
원문 보기